Login to Your Account

AEterna's Stock Slides On Missed Endpoint In Neovastat Renal Trial

By Kim Coghill

Thursday, September 25, 2003
Although AEterna Laboratories Inc. missed the primary endpoint in a Phase III trial of Neovastat in renal-cell carcinoma, the company Wednesday said a subgroup of earlier-stage cancer patients demonstrated a significant survival benefit. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription